Keywords: Reliance GeneMedix, EU marketing authorization, Epostim, Erythropoietin, Anemia, EMA, Europe

Reliance GeneMedix pulls EU marketing application for Epostim

Article | 07 April 2011

Print This

The European Medicines Agency (EMA) says it has been formally notified by UK-based Reliance GeneMedix (GMX: LN) of its decision ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in